4Pham DQ, Nogid A, Plakogiannis R. Sitagliptin : a novel agent for the management of type 2 diabetes mellitus [ J ] . Am J Health Syst Pharm,2008,65 (6) :521.
3Elrishi MA, Jarvis J, Khunti K, et al. Insulin glargine and its role in glycaemic management of type 2 diabetes[J]. Expert Opin Drug Metab Toxicol, 2008, 4 ( 8 ) : 1 099.
4Hagenmeyer EG, Schadlich PK, Koster AD, et al.Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues[J]. Dtsch Med Wochenschr, 2009,134(12) : 565.
5White RD.The treat-to-target A1c approach to control type 2 diabetes and prevent complications [J]. Adv Ther, 2007, 24(3) :545.
6Kuritzky L. Addition of basal insulin to oral antidiabetic agents: a goal-directed approach to type 2 diabetes therapy [J]. Med Gen Med, 2006,8(4) : 34.
8Vahl TP, Paty BW, Fuller BD, et al.Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab, 2003,88:1772-1779.
9Delgado E, Luque MA, Alcantara A et al. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides,1995,16:225-229.
10Montrose-Rafizadeh C, Yang H, Wang Y,et al. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol,1997,172:275-283.
